Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Tenofovir alafenamide works well and improves kidney and bone markers in older people living with HIV

A co-formulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older

Published
10 November 2016
By
Liz Highleyman
Darunavir/ritonavir & lamivudine matches triple-drug therapy

Simplifying antiretroviral therapy to a two-drug combination of lamivudine plus the protease inhibitor darunavir (Prezista) boosted by ritonavir is just as effective as a three-drug regimen in

Published
31 October 2016
By
Keith Alcorn
Two-drug HIV therapy just as effective as three-drug therapy

Simplification of an antiretroviral treatment to a boosted protease inhibitor and the nucleoside analogue lamivudine (a dual regimen) is highly effective in people switching from a stable three-drug

Published
25 October 2016
By
Keith Alcorn
Doctors in Netherlands observe higher than expected dolutegravir treatment discontinuation rate

Almost one in seven people in a Dutch clinic population stopped treatment with the HIV integrase inhibitor dolutegravir because of side-effects, investigators from the Netherlands report in

Published
13 October 2016
By
Michael Carter
Spanish study gives reassurance: small HIV blips do not predict treatment failure

A very low viral load (20-49 copies/ml) during HIV therapy does not increase the risk of the subsequent virological failure of treatment (viral load above 200 copies/ml), according

Published
21 September 2016
By
Michael Carter
Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

Published
20 September 2016
From
BETA blog
Most people taking second-line ART in sub-Saharan Africa achieve viral suppression but there's a need for third-line treatment options

Approximately 85% of people switched to protease inhibitor-based second-line antiretroviral (ART) in sub-Saharan Africa achieve and maintain an undetectable viral load with their new regimen, according to research

Published
12 August 2016
By
Michael Carter
Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

Frontier Biotechnologies Inc. today reported that a phase 3 clinical trial (TALENT Study) of its lead product albuvirtide meets primary objective based on an interim analysis. The results demonstrated that once-weekly given albuvirtide plus ritonavir-boosted lopinavir was non-inferior to WHO-recommended second-line three-drug regimen (control) at 48-week in treatment experienced HIV-1 infected adults. In addition, patients administered with albuvirtide showed statistically better renal safety than those taking the control regimen containing tenofovir disoproxil fumarate.

Published
07 June 2016
From
Frontier Biotech press release
HIV and drug resistance

A recent study found more resistance to the antiretroviral medicine tenofovir than had previously been reported, with 20% resistance to tenofovir in patients with treatment failure in Europe and over 50% resistance in patients with treatment failure in sub-Saharan Africa... The study underlines the importance of rapidly identifying treatment failure through routine measurement of viral load suppression—this is the basis of the third pillar of UNAIDS’ 90–90–90 treatment target, that 90% of people accessing HIV treatment have suppressed viral loads.

Published
09 February 2016
From
UNAIDS
People taking a large number of non-HIV-related medications more likely to stop or change HIV drugs

HIV-positive patients who are taking a large number of medications for the treatment of non-HIV-related conditions are at increased risk of stopping or changing their antiretroviral therapy (ART),

Published
27 January 2016
By
Michael Carter
← First12345...26Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.